FBIOP
Fortress Biotech Pref A·NASDAQ
--
--(--)
--
--(--)
0.88 / 10
Underperform
Fundamental analysis reveals subpar quality with a score of 0.9/10; key metrics such as ROA (-16.9%) and net profit margin (-22.5%) rank in the lowest quartile, historically associated with negative returns. Only the Total profit YoY growth (71.1%) shows a positive read, but it remains in a mid-tier quartile with limited historical success, underscoring the need for operational enhancement.
Analysis Checks(0/4)
ROA (%)
Value-16.90
Score0/3
Weight33.93%
1M Return-4.91%
Value-16.90
Score0/3
Weight33.93%
1M Return-4.91%
Fixed assets turnover ratio
Value2.94
Score1/3
Weight14.52%
1M Return-1.63%
Value2.94
Score1/3
Weight14.52%
1M Return-1.63%
Total profit (YoY growth rate %)
Value71.11
Score1/3
Weight17.62%
1M Return-1.83%
Value71.11
Score1/3
Weight17.62%
1M Return-1.83%
Annualized net profit margin on total assets (%)
Value-22.54
Score0/3
Weight33.93%
1M Return-4.91%
Value-22.54
Score0/3
Weight33.93%
1M Return-4.91%
ROA (%)
Value-16.90
Score0/3
Weight33.93%
1M Return-4.91%
Value-16.90
Score0/3
Weight33.93%
1M Return-4.91%
Total profit (YoY growth rate %)
Value71.11
Score1/3
Weight17.62%
1M Return-1.83%
Value71.11
Score1/3
Weight17.62%
1M Return-1.83%
Fixed assets turnover ratio
Value2.94
Score1/3
Weight14.52%
1M Return-1.63%
Value2.94
Score1/3
Weight14.52%
1M Return-1.63%
Annualized net profit margin on total assets (%)
Value-22.54
Score0/3
Weight33.93%
1M Return-4.91%
Value-22.54
Score0/3
Weight33.93%
1M Return-4.91%
Is FBIOP undervalued or overvalued?
- FBIOP scores 0.88/10 on fundamentals and holds a Premium valuation at present. Backed by its 13.58% ROE, -86.41% net margin, -1.71 P/E ratio, 0.63 P/B ratio, and 96.62% earnings growth, these metrics solidify its Underperform investment rating.
